Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
暂无分享,去创建一个
Toshio Sada | Makoto Mizuno | H. Koike | Mikio Kato | Hiroyuki Koike | M. Mizuno | Mikio Kato | T. Sada
[1] S. Tazawa,et al. Krh‐594, A New Angiotensin At1 Receptor Antagonist, Ameliorates Nephropathy And Hyperlipidaemia In Diabetic Spontaneously Hypertensive Rats , 2000, Clinical and experimental pharmacology & physiology.
[2] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[3] M. Kohzuki,et al. Antihypertensive and renal‐protective effects of losartan in streptozotocin diabetic rats , 1995, Journal of hypertension.
[4] D. Wheeler,et al. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] B. Kasiske,et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[7] E. Jaimes,et al. Angiotensin II induces superoxide anion production by mesangial cells. , 1998, Kidney international.
[8] H. Koike,et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. , 1995, European journal of pharmacology.
[9] S. Ross,et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. , 2000, Kidney international.
[10] G. Appel,et al. Lipid abnormalities in renal disease. , 1991, Kidney international.
[11] L. Ruilope,et al. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. , 1997, American journal of hypertension.
[12] R. DeFronzo,et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. , 1989, Metabolism: clinical and experimental.
[13] J. Zhang,et al. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor. , 2000, Hypertension research : official journal of the Japanese Society of Hypertension.
[14] N. Perico,et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. , 1993, Journal of the American Society of Nephrology : JASN.
[15] W. Hsueh,et al. Angiotensin II causes mesangial cell hypertrophy. , 1993, Hypertension.
[16] Y. Takayama,et al. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.
[17] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[18] K. Kędziora-Kornatowska,et al. Effect of angiotensin convertase inhibitors and AT1 angiotensin receptor antagonists on the development of oxidative stress in the kidney of diabetic rats. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[19] N. Hirawa,et al. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. , 1994, Hypertension.
[20] F. Locatelli,et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] J. Baynes. Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.
[22] N. Perico,et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. , 1999, American journal of physiology. Renal physiology.
[23] H. Rennke,et al. Role for angiotensin II in an overt functional proteinuria. , 1986, Kidney international.
[24] N. Hirawa,et al. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus. , 1999, American journal of hypertension.
[25] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[26] D. de Zeeuw,et al. Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. , 2000, Diabetic medicine : a journal of the British Diabetic Association.
[27] J. Chan,et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. , 1992, BMJ.
[28] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[29] G. Etgen,et al. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. , 2000, Metabolism: clinical and experimental.
[30] R. Harris,et al. Angiotensin actions in the kidney: renewed insight into the old hormone. , 1991, Kidney international.
[31] H. Hidai. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management. , 2000, Kidney international.
[32] Ashutosh Kumar Singh,et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. , 1999, Diabetes.
[33] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[34] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[35] S. Anderson,et al. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. , 1996, Journal of the American Society of Nephrology : JASN.